B
Bull
Bull · 25%MBX
$15.58
Scenario price
$50.710
+1.962 (+3.87%)At close
Loading chart…
- High
- 51.300
- Open
- 49.150
- VWAP
- 50.25
- Volume
- 601.77K
- Mkt Cap
- —
- Low
- 48.730
- Amount
- 30.24M
- EV/EBITDA, TTM
- 0.00
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.
AI analysis of MBX Biosciences Inc (MBX)
HoldCurrently, MBX Biosciences is not a strong buy due to its low RSI of 27.595, indicating oversold conditions, and a significant net loss of $37.1 million in Q2 2026. However, the potential upside is notable with analyst price targets suggesting a range from $88 to $150, indicating a possible upside of 65% to 181% from the current price of $53.24. The main risk is the ongoing financial losses, which could impact investor confidence and future funding capabilities.
Valuation Metrics
The current forward P/E ratio for MBX Biosciences Inc (MBX) is 0.00, compared to its 5-year average forward P/E of -5.80.
Alphio AI Price Scenarios for MBX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MBX
Events Timeline
News
9.508-06seekingalphaMBX Biosciences Reports Q2 2026 Financial Results
5.007-15GlobenewswireAttovia Appoints New Independent Director
5.007-15NewsfilterAttovia Appoints New Independent Director
2.007-14CNBCAnalysis of Major Stock Movements
- 9.006-12seekingalpha
MBX Biosciences Shares Drop After Trial Results Fall Short
MBX FAQ — answered by Alphio AI
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency. It operates in the Healthcare sector.
Currently, MBX Biosciences is not a strong buy due to its low RSI of 27.595, indicating oversold conditions, and a significant net loss of $37.1 million in Q2 2026. However, the potential upside is notable with analyst price targets suggesting a range from $88 to $150, indicating a possible upside of 65% to 181% from the current price of $53.24. The main risk is the ongoing financial losses, which could impact investor confidence and future funding capabilities.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.